Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 14, keine Gesamtzahl für „should“
Suchtreffer
Begriffe & Kennungen
Emend · 4.5 · Warfarin In patients on chronic warfarin therapy, the prothrombin time (INR) should be monitored closely durin
Eintrag öffnenEmselex · 4.5 · CYP3A4 inhibitors Darifenacin should not be used together with potent CYP3A4 inhibitors (see section 4.3) such
Eintrag öffnenEmselex · 4.5 · CYP3A4 inhibitors Darifenacin should not be used together with potent CYP3A4 inhibitors (see section 4.3) such
Eintrag öffnenEmselex · 4.5 · Digoxin Therapeutic drug monitoring for digoxin should be performed when initiating and ending darifenacin tre
Eintrag öffnenEmselex · 4.5 · Digoxin Therapeutic drug monitoring for digoxin should be performed when initiating and ending darifenacin tre
Eintrag öffnenEmselex · 4.5 · Warfarin Standard therapeutic prothrombin time monitoring for warfarin should be continued. The effect of warf
Eintrag öffnenEmselex · 4.5 · Warfarin Standard therapeutic prothrombin time monitoring for warfarin should be continued. The effect of warf
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Krka d.d. · 4.5 · Emtricitabine/Tenofovir disoproxil Krka d.d. should not be administered concomitantly with other medicinal pro
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Krka d.d. · 4.5 · Use of Emtricitabine/Tenofovir disoproxil Krka d.d. should be avoided with concurrent or recent use of a nephr
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Krka · 4.5 · Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly with other medicinal products
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Krka · 4.5 · Use of Emtricitabine/Tenofovir disoproxil Krka should be avoided with concurrent or recent use of a nephrotoxi
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Mylan · 4.5 · Emtricitabine/tenofovir disoproxil should not be administered concomitantly with other medicinal products cont
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Mylan · 4.5 · GS-331007 2: AUC: ↔ The combination should be used with caution Cmax: ↔ with frequent renal monitoring, if oth
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Mylan · 4.5 · GS-331007 2: AUC: ↔ The combination should be used with caution Cmax: ↔ with frequent renal monitoring, if oth
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Mylan · 4.5 · Use of emtricitabine/tenofovir disoproxil should be avoided with concurrent or recent use of a nephrotoxic med
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Mylan · 4.5 · Velpatasvir: The combination should be used with caution AUC: ↔ with frequent renal monitoring (see Cmax: ↓ 24
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Mylan · 4.5 · Velpatasvir: The combination should be used with caution AUC: ↔ with frequent renal monitoring (see section Cm
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Mylan · 4.5 · Velpatasvir: The combination should be used with caution with frequent renal monitoring (see AUC: ↑ 142% secti
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Zentiva · 4.5 · Atazanavir: The combination should be used AUC: ↔ with caution with frequent renal Cmax: ↔ monitoring (see sec
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Zentiva · 4.5 · Atazanavir: The combination should be used AUC: ↔ with caution with frequent renal Cmax: ↔ monitoring, if othe
Eintrag öffnen